

# 20<sup>TH</sup>

# EADO CONGRESS

**April 4<sup>th</sup>-6<sup>th</sup>, 2024**

PARIS, FRANCE

PALAIS DES CONGRÈS VERSAILLES

**FINAL  
PROGRAM**

UPDATE 05/04/2024



This activity is provided by EADO. This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

ON-SITE CONGRESS WITH  
ADDITIONAL VIRTUAL ACCESS

[WWW.EADO2024.COM](http://WWW.EADO2024.COM)

# CONTENT

<b>Welcome Message</b>	3
<b>Congress at a Glance</b>	4
<b>Congress History</b>	5
<b>Congress Venue</b>	6
<b>Floor Plan</b>	8
<b>Congress Faculty</b>	12
<b>Additional Speakers</b>	14
<b>Call for Abstracts</b>	16
<b>General Information from A–Z</b>	19
<b>Scientific Program at a Glance</b>	24
<b>Scientific Program</b>	27
Thursday, April 4 <sup>th</sup> , 2024	28
Friday, April 5 <sup>th</sup> , 2024	36
Saturday, April 6 <sup>th</sup> , 2024	46
<b>Satellite Symposia at a Glance</b>	52
<b>Satellite Symposia Program</b>	53

## WELCOME MESSAGE

### Dear Colleagues,

We have the great pleasure to invite you to join us for the 20<sup>th</sup> EADO Congress taking place as an on-site meeting with additional virtual access from April 4–6, 2024 in the amazing city of Paris, France.


The European Association of Dermato-Oncology Congress is the largest conference in dermatology worldwide, there are no competing meetings in this field. Over 1,400 participants from Europe and around the world are expected to attend.

The meeting provides updated scientific and clinical achievements in a wide spectrum of skin tumors including melanoma, keratinocyte carcinomas and rare malignant neoplasms. The world's leading experts have been invited as speakers and will offer you the opportunity to gain a comprehensive insight into all areas of dermatology.


Paris is the political, environmental and cultural center of France. Close to the heart of Paris, the congress center **Versailles Palais des Congrès** offers renovated top-of-the-range meeting facilities and a less urban and more tree-lined environment. The venue is well accessible by the Metro station "Versailles Château Rive Gauche" and offers all the prerequisites for an unforgettable congress experience.

Looking forward to welcoming you online or in Paris in April 2024!



  
Prof. Dr. Céleste Lebbé  
Paris, France  
Congress President



  
Prof. Dr. Claus Garbe  
Tuebingen, Germany  
Congress President

# CONGRESS AT A GLANCE

## Congress Organizer

**MEDCONCEPT** 

MedConcept GmbH  
Friedenstr. 58  
15366 Neuenhagen bei Berlin  
Germany  
Phone: +49 (0) 334242689-30  
Fax: +49 (0) 334242689-40  
E-Mail: congress@eado2024.com

## Congress Venue

Versailles Palais des Congrès  
10 rue de la Chancellerie  
78 000 Versailles, France  
[www.versaillespalaisdescongres.com/en/](http://www.versaillespalaisdescongres.com/en/)

## Congress Website and Virtual Platform

[www.eado2024.com](http://www.eado2024.com)

## Congress Format

On-site meeting with  
additional virtual access

## Expected Number of Participants

1,000

## Congress Language

English

## Congress Presidents

Claus Garbe, Tuebingen, Germany  
Céleste Lebbé, Paris, France

## French Organizing Committee


Caroline Robert, Paris, France  
Philippe Saiag, Versailles, France  
**In collaboration with:**  
Barouyr Baroudjian, Paris, France  
Stephane Dalle, Lyon, France  
Adele de Masson, Paris, France  
Julie Delyon, Paris, France  
Brigitte Dréno, Nantes, France  
Nicolas Dumaz, Paris, France  
Caroline Dutriaux, Bordeaux, France  
Caroline Gaudy-Marqueste, Marseille, France  
Eve Maubec, Paris, France  
Henri Montaudié, Nice, France  
Laurent Mortier, Lille, France  
Samia Mourah, Paris, France  
Charlée Nardin, Besançon, France  
Benedicte Oules, Paris, France  
Cécile Pagès, Toulouse, France  
Anne Pham Ledard, Bordeaux, France  
Sophie Piperno-Neumann, Paris, France

## European Scientific Committee

Petr Arenberger, Prague, Czech Republic  
Veronique Bataille, London, UK  
Matilda Bylaite, Vilnius, Lithuania  
Veronique Del Marmol, Brussels, Belgium  
Reinhard Dummer, Zurich, Switzerland  
Ana-Maria Forsea, Bucharest, Romania  
Catherine Harwood, London, UK  
Axel Hauschild, Kiel, Germany  
Christoph Höller, Vienna, Austria  
Lidija Kandolf, Belgrade, Serbia  
Roland Kaufmann, Frankfurt, Germany  
Nicole Kelleners-Smeets, Maastricht, The Netherlands  
Amilios Lallas, Thessaloniki, Greece  
Bohdan Lytvynenko, Kyiv, Ukraine  
Josep Malvehy, Barcelona, Spain  
David Moreno-Ramirez, Seville, Spain  
Judit Olah, Szeged, Hungary  
Hubert Pehamberger, Vienna, Austria  
Giovanni Pellacani, Rome, Italy  
Ketty Peris, Rome, Italy  
Mirna Šitum, Zagreb, Croatia  
Eggert Stockfleth, Bochum, Germany  
Alexander Stratigos, Athens, Greece  
Ricardo Vieira, Coimbra, Portugal  
Georg Weinlich, Innsbruck, Austria  
Zalaudek



The EADO (European Association of Dermato-Oncology) is an independent non-profit organization dedicated to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research. One mission of the EADO is to support and organise meetings dedicated to the presentation of new research findings, the exchange of information and education for its members in the field of dermato-oncology. The first EADO Congress was held 2001 in Vienna, Austria.



- 2001 – Vienna, Austria
- 2003 – Marseille, France
- 2006 – Rome, Italy
- 2008 – Marseille, France
- 2009 – Vienna, Austria
- 2010 – Athens, Greece
- 2011 – Nantes, France
- 2012 – Barcelona, Spain
- 2013 – Hamburg, Germany
- 2014 – Vilnius, Lithuania
- 2015 – Marseille, France
- 2016 – Vienna, Austria
- 2017 – Athens, Greece
- 2018 – Barcelona, Spain
- 2019 – Paris, France
- 2020 – Virtual Meeting
- 2021 – Virtual Meeting
- 2022 – Seville, Spain
- 2023 – Rome, Italy
- 2024 – Paris, France
- 2025 – Athens, Greece
- 2026 – Prague, Czech Republic
- 2027 – Barcelona, Spain
- 2028 – Vienna, Austria
- 2029 – Maastricht, The Netherlands

[www.eado.org](http://www.eado.org)

## CONGRESS VENUE

Close to the heart of Paris, **Versailles Palais des Congrès** offers 3200 m<sup>2</sup> of completely renovated top-of-the-range meeting facilities for conferences and a less urban and more tree-lined environment. The venue is well accessible by the Metro station „Versailles Château Rive Gauche“. Versailles is a city with a rich history and majestic monuments and offers all the prerequisites for an unforgettable congress experience.



## VERSAILLES PALAIS DES CONGRÈS








## Airports

Paris has two international airports, Paris-Charles-de-Gaulle (CDG) in the Northeast and Paris-Orly (ORY) in the South. Paris-Charles-de-Gaulle is Paris main international airport. However, the „Palais des Congrès“ is easier to reach from Paris-Orly.

**CONGRESS  
VENUE  
FLOOR PLAN**




**BASEMENT FLOOR**






## GROUND FLOOR




**CONGRESS  
VENUE  
FLOOR PLAN**

**FIRST FLOOR**



## SECOND FLOOR



# CONGRESS FACULTY

## A

**Dr. Teresa Amaral**  
Tuebingen, Germany

**Prof. Petr Arenberger**  
Prague, Czech Republic

**Prof. Giuseppe Argenziano**  
Naples, Italy

**Prof. Chalid Assaf**  
Krefeld, Germany

## B

**Dr. Barouyr Baroudjian**  
Paris, France

**Dr. Veronique Bataille**  
London, United Kingdom

**Jürgen C. Becker**  
Essen and Heidelberg, Germany

**Prof. Astrid Blom**  
Boulogne, France

## D

**Prof. Stephane Dalle**  
Lyon, France

**Dr. Arnaud de la Fouchardière**  
Lyon, France

**Dr. Adele de Masson**  
Paris, France

**Prof. Veronique del Marmol**  
Brussels, Belgium

**Prof. Julie Delyon**  
Paris, France

**Prof. Brigitte Dréno**  
Nantes, France

**Dr. Nicolas Dumaz**  
Paris, France

**Prof. Reinhard Dummer**  
Zurich, Switzerland

**Dr. Caroline Dutriaux**  
Bordeaux, France

## E

**Prof. Alexander Eggermont**  
Utrecht, The Netherlands

**Prof. Thomas Eigentler**  
Berlin, Germany

## F

**Prof. Maria Concetta Fagnoli**  
L'Aquila, Italy

**Prof. Lukas Flatz**  
Tuebingen, Germany

**Prof. Andrea Forschner**  
Tuebingen, Germany

**Prof. Ana-Maria Forsea**  
Bucharest, Romania

## G

**Prof. Claus Garbe**  
Tuebingen, Germany

**Prof. Caroline Gaudy-Marqueste**  
Marseille, France

**Prof. Alexandra Geusau**  
Vienna, Austria

**Prof. Ralf Gutzmer**  
Minden, Germany

## H

**Prof. John Haanen**  
Amsterdam, The Netherlands

**Prof. Catherine Harwood**  
London, United Kingdom

**Prof. Jessica Hassel**  
Heidelberg, Germany

**Prof. Axel Hauschild**  
Kiel, Germany

**Prof. Christoph Höller**  
Vienna, Austria

## K

**Prof. Lidija Kandolf**  
Belgrade, Serbia

**Prof. Roland Kaufmann**  
Frankfurt, Germany

**Dr. Nicole Kelleners-Smeets**  
Maastricht, The Netherlands

---

**L**

---

**Prof. Aimilos Lallas**  
Thessaloniki, Greece

**Prof. Ulrike Leiter-Stöppke**  
Tuebingen, Germany

**Prof. Céleste Lebbé**  
Paris, France

**Caterina Longo**  
Modena, Italy

**Prof. Paul Lorigan**  
Manchester, United Kingdom

---

**M**

---

**Prof. Josep Malvehy**  
Barcelona, Spain

**Prof. Eve Maubec**  
Paris, France

**Prof. Friedegund Meier**  
Dresden, Germany

**Prof. Olivier Michielin**  
Geneva, Switzerland

**Prof. Henri Montaudié**  
Nice, France

**Prof. David Moreno-Ramirez**  
Seville, Spain

**Prof. Laurent Mortier**  
Lille, France

**Prof. Samia Mourah**  
Paris, France

---

**N**

---

**Dr. Charlée Nardin**  
Besançon, France

---

**O**

---

**Dr. Benedicte Oules**  
Paris, France

---

**P**

---

**Dr. Cécile Pagès**  
Toulouse, France

**Dr. Sapna Patel**  
Houston, USA

**Prof. Ketty Peris**  
Rome, Italy

**Prof. Anne Pham Ledard**  
Bordeaux, France

**Dr. Sophie Piperno-Neumann**  
Paris, France

**Dr. Susana Puig**  
Barcelona, Spain

---

**R**

---

**Prof. Caroline Robert**  
Paris, France

---

**S**

---

**Prof. Philippe Saiag**  
Versailles, France

**Prof. Mahtab Samimi**  
Tours, France

**Prof. Dirk Schadendorf**  
Essen, Germany

**Dr. Vincent Sibaud**  
Toulouse, France

**Prof. Alexander Stratigos**  
Athens, Greece

**Prof. Mariano Suppa**  
Brussels, Belgium

---

**T**

---

**Prof. Hussein Tawbi**  
Houston, United States

---

**V**

---

**Dr. Ricardo Vieira**  
Coimbra, Portugal

---

**W**

---

**Prof. Julia Welzel**  
Augsburg, Germany

---

**Z**

---

**Prof. Iris Zalaudek**  
Trieste, Italy

**Prof. Laurence Zitvogel**  
Paris, France

## ADDITIONAL SPEAKER

### A

**Prof. Monika Arenbergerova**  
Prague, Czech Republic

### B

**Prof. Philippe Bahadoran**  
Nice, France

**Prof. Tobias Bald**  
Bonn, Germany

**Prof. Lieve Brochez**  
Gent, Belgium

**Dr. Florence Brunet Possenti**  
Paris, France

**Prof. Christopher Bunker**  
London, UK

### C

**Prof. Elisa Cinotti**  
Siena, Italy

**Prof. Richard Cowan**  
Manchester, UK

**Dr. Stefania Cuzzubbo**  
Paris, France

### D

**Dr. Clio Dessinioti**  
Athens, Greece

**Prof. Michele Donati**  
Rome, Italy

### E

**Dr. Eva Ellebaek**  
Copenhagen, Denmark

### G

**Dr. Glenn Geidel**  
Hamburg, Germany

**Prof. Dr. Petter Gjersvik**  
Oslo, Norway

**Dr. Isabella Glitza**  
Houston, United States

**Prof. Emmanuella Guenova**  
Geneva, Switzerland

### H

**Dr. Omar Hasan Ali**  
Zurich, Switzerland

### L

**Dr. Konstantinos Liopyris**  
Athens, Greece

**Dr. Pierre Loap**  
Paris, France

### M

**Dr. Ivan Marquez-Rodas**  
Madrid, Spain

**Dr. Jilliana Monnier**  
Marseille, France

**Dr. Victor Moreno**  
Madrid, Spain

**Dr. Nelson Moss**  
New York, United States

**Prof. Klara Mosterd**  
Maastricht, The Netherlands

### N

**Dr. Mirjam Nägeli**  
Zurich, Switzerland

**Dr. Paul Nathan**  
Northwood, United Kingdom

**Prof. Dario Neri**  
Zurich, Switzerland

**Prof. Ingo Nindl**  
Berlin Germany



**P**

---

**Dr. Javiera Perez-Anker**  
Barcelona, Spain

**Dr. Elsemieke Plasmeijer**  
Amsterdam, The Netherlands

**R**

---

**Dr. Egle Ramelyte**  
Zurich, Switzerland

**Dr. Emily Ruiz**  
Boston, USA

**U**

---

**Prof. Hisashi Uhara**  
Sapporo, Japan

**V**

---

**Dr. Charles Valery**  
Paris, France

**Prof. Dagmar von Bubnoff**  
Lübeck, Germany

**W**

---

**Dr. Katarina Wunderlich**  
Wuppertal, Germany

**Z**

---

**Prof. Axel zur Hausen**  
Maastricht, The Netherlands

# CALL FOR ABSTRACTS

## IMPORTANT DEADLINES

February 15, 2024	Deadline for abstract submission
February 29, 2024	Notification of acceptance of abstracts
March 1, 2024	Start of Late-breaking & trials in progress abstract submission (until March 7, 2024)
March 14, 2024	Late-breaking & trials in progress notification of acceptance
March 15, 2024	Early registration fee deadline
October 20, 2024	End of on-demand service

### Call for Abstracts

#### Abstract Submission Deadline: February 15, 2024

All those interested in presenting abstracts at the 20<sup>th</sup> EADO Congress are invited to submit their work to the Program Committee for review. Selected abstracts will be chosen for an oral presentation during the free communications sessions or as printed posters. **The acceptance of an abstract does not include the congress registration. Authors must be registered for the congress before March 18, 2024 in order to present their work.**

### Abstract Topics

Actinic keratoses  
Basal cell carcinoma  
Cutaneous sarcoma  
Cutaneous T- and B-cell lymphoma  
Melanoma – Epidemiology and diagnostics  
Melanoma – Experimental and translational studies  
Melanoma – Immune checkpoint inhibitor (ICI) therapy  
Melanoma – Surgery  
Melanoma – Systemic therapy other than ICI therapy  
Merkel cell carcinoma  
Rare tumors  
Squamous cell carcinoma

### Abstract Guidelines

- Abstracts may be **submitted online via the congress website**. Abstracts submitted by e-mail will not be accepted.
- Abstracts must be received by the **announced deadline**. Abstracts received after the deadline will not be considered.
- The **title** should be as brief as possible but long enough to clearly indicate the nature of the study. Abbreviations must not be used in the title. The title should not be written entirely in capital letters (e.g. NOT LIKE THIS).
- Please indicate the **topic** from the abstract topics list and your preferred type of presentation (oral or poster). The Committee will endeavor to schedule abstracts according to authors' preferences but reserves the right to decide on the final form of presentation.
- **Encore abstracts** will be accepted unless they have been published in scientific journals.
- Please structure the abstract as follows:
  - **Introduction & Objectives:** Describe the background and the purpose of the study
  - **Materials & Methods:** Describe the material and methods used to design the study
  - **Results:** Describe your results in a logical sequence
  - **Conclusions:** Emphasise new and important aspects of the study and conclusions that are drawn from them
- The text shall not exceed 350 words including spaces (excluding title, authors bibliography and key words). The submission program will automatically calculate the number of characters in your abstract and will not allow submissions that exceed the maximum number of characters.
- It is acceptable to include up to two **tables, graphics, or images (jpg, jpeg, png, gif format, maximum size 2 MB in total)** as part of the abstract.
- All abstracts must be submitted and presented in clear **English** with accurate grammar and spelling of a quality suitable for publication. Abstracts will not be edited by the Congress Secretariat prior to publication, therefore please check the grammar and spelling carefully.
- Please use generic names. **The use of commercial drug names, brands and registered trademarks are strictly prohibited**. Drugs should be referred to by the active substance or pharmacological designation.
- No mention of pharmaceutical company names should be included in the abstract.

### Patient Privacy / Clinical Photography

Photographs should at all times protect the privacy and identity of the subject. Eyes should be blacked out. The source of the photographs must also be declared if not the property of the presenter. This is to prevent the use of photographic material without permission.

### Oral Presentations

Selected abstracts will be chosen for an oral presentation during the free communications sessions. The presenting author does not have to be the first author.

### Poster Exhibition

Abstracts selected for poster will be presented as posters during the congress. The Poster Exhibition is located on the 2nd floor.

### Publication

All accepted abstracts will be published in the digital Book of Abstracts which will be available for download on the congress website from April 3, 2024 onwards. The Book of Abstract will also be published on the EADO website under Events & Training / EADO Congress after the conference.

## Registration

Please note that the acceptance of an abstract does not include the congress registration. The presenting author must be a registered participant, otherwise the abstract will not be reviewed and waived from the program.

## Abstracts Awards

The EADO is pleased to offer the following awards for abstracts submitted for oral and poster presentation:

### Poster Awards

The best Poster on display in each of the following 3 categories will be awarded with 500 € each and a free registration to the next EADO Congress.

- › Melanoma diagnosis & treatment
- › Non-Melanoma Skin Cancer diagnosis & treatment
- › Basic research, genetics and epidemiology of skin cancer

### Oral Communication Award

The best Oral Communication will be awarded with 500€ and a free registration to the next EADO Congress. All prize-winning abstracts will be selected by the Poster & Oral Communication Committee. Further information on when the prizes will be awarded will follow.

## CONGRESS ORGANIZATION

**MEDCONCEPT** 

Gesellschaft für  
medizinische Projekte mbH  
Friedenstr. 58  
15366 Neuenhagen bei Berlin  
Germany

Phone **+49 (0)3342 – 42 68 930**  
Email: [congress@eado2024.com](mailto:congress@eado2024.com)  
[www.medconcept.org](http://www.medconcept.org)

GENERAL  
INFORMATION  
FROM A-Z

### Accommodation

A limited number of rooms at selected hotels close to the conference venue Palais des Congrès and within Paris has been reserved at reduced rates. Further information is available on the congress website at <https://eado2024.com/accommodation/>. Please note that hotel capacities in Versailles and Paris are limited and that there are Spring Holidays in Paris from April 8–21, 2024. Therefore, we strongly recommend to book your rooms early!

### Badges

The name badge is the official congress identification document. Please wear your badge at all times in order to gain entry into the session rooms and exhibition area. Admission to the congress area will not be permitted without badge identification. Kindly note that for the reprinting of lost or forgotten badges, an administrative fee of 20 Euro will be charged.

### Cancellation Policy

Cancellations must be received in writing to [registrations@eado2024.com](mailto:registrations@eado2024.com) by February 20, 2024. No refunds will be granted after that date. A processing fee of 30 Euro will be deducted from each cancelled registration. Substitutions are possible. To substitute a registration, please send an email including the name of the original registrant and the name of the person substituting to [registrations@eado2024.com](mailto:registrations@eado2024.com).

### Certificate of Attendance

To get the Certificate of Attendance, you will receive an email with a link to the EACCME questionnaire 14 days after the congress. After completing the questionnaire, your certificate will be emailed to you.

### Cloakroom and Luggage

The cloakroom is located next to the registration desk on the ground floor, please refer to the floor plan for orientation. As storage space is limited, we recommend all guests to store their baggage at the hotel. Please note that the organizer and the congress venue will not accept any liability for any items left behind.

### CME Credits

In order to receive the CME points, please have your name badge scanned daily at the entrance / registration desk in the foyer; this serves to record your attendance and the corresponding allocation of the CME points. You will receive your certificates of attendance by e-mail after the event. (Please note that you will need to fill in the official EACCME questionnaire, which you will also receive by e-mail after the congress).

The 20<sup>th</sup> European Association of Dermato-Oncology (EADO) Congress 2024, Palais des Congrès Versailles, 10 rue de la Chancellerie, 78 000 Versailles, France, France, 04/04/2024–06/04/2024 organized by The European Association of Dermato-Oncology (EADO) has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 17.0 European CME credits (ECMEC®s).

### **Coffee Breaks and Refreshments**

Coffee breaks and wrapped lunch to go will be served in the exhibition area on the ground floor. It is not allowed to bring food into the Amphitheatre.

### **Congress Bag**

Congress bags can be picked up at the registration desk.

### **Congress Program**

Please note that there will be no printed program provided on-site for sustainability reasons.

The full program can be viewed via the congress app or can be downloaded as a pdf from the congress website. All registered delegates will receive further information by email shortly before the congress. Delegates may also scan the QR code available at the Registration Desk using their iPhone or Android.

### **Congress Venue**

Versailles Palais des Congrès

10 rue de la Chancellerie

78 000 Versailles, France

[www.versaillespalaisdescongres.com/en/](http://www.versaillespalaisdescongres.com/en/)

### **Exhibition**

A commercial exhibition will run during the congress. Visit the onsite industrial exhibition to get in touch with exhibitors, colleagues, collaborators and friends. Don't forget to visit the additional virtual information provided by the sponsors via the Congress Website as of 20th April at: [www.edo2024.com](http://www.edo2024.com)

### **Exhibition Opening Hours**

Thursday, April 4                    07:30–18:30

Friday, April 5                      07:30–17:45

Saturday, April 6                    08:30–13:00

### **First Aid**

In case of emergency, please go to the First Aid room. The French number for the ambulance service is 15.

### **Insurance**

The organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect of health and travel insurance.

### **Invitation Letter**

The congress organizers would be pleased to send a formal letter of invitation to delegates who require an invitation letter for visa purposes. It is understood that such an invitation is intended to help potential delegates obtain a visa or to raise funds. The letter of invitation does not imply a commitment from the congress to provide any financial support.

Further information is available on the Congress Website.

### **Language and Translation**

The official language of the meeting is English. Simultaneous translation will not be provided.



### Liability Disclaimer

In the unlikely occurrence that the congress must be cancelled or postponed due to circumstances beyond the control of the organizers (natural disasters, political, social or economic events or other unforeseen events beyond control), the organizers cannot be held liable for any costs incurred by the event attendee. The organizer will record images during the event. By virtue of attendance, attendees agree to the organizer's usage of these recordings on the website and for marketing.

### Lost & Found

Please hand in all found items at the registration desk. A lost and found box will be provided there.

### Parking Facilities

The venue offers 600 parking spaces.

### Photography, audio, video and mobile phone policy

Audio, photo and video recording by any device is strictly prohibited during all scientific sessions, unless prior permission is obtained from the congress organizer.

### Program Changes

The organizer reserves the right to make changes to the event program at short notice if necessary. This does not result in any reimbursement claims. Program changes will be announced during the congress.

### Questions to Speakers

Questions can be asked online via the congress app. In addition to that Wireless microphones will be at your disposal during the discussion period in all sessions. Delegates wishing to participate in the discussion periods should make their way to the nearest microphone placed in the aisles.

### Registration

Registration is only possible by using the online portal on the congress website:

<https://eado2024.com/registration/>

Category / Fee	Early Bird Fee On-Site Attendance until March 15, 2024	Regular & Onsite Fee On-Site Attendance from March 16, 2024	Virtual Attendance
EADO Member	500 €	700 €	500 €
Non-EADO Member	600 €	750 €	600 €
Resident*	200 €	240 €	200 €
Student*	100 €	150 €	100 €
Day Tickets	250 €	250 €	–

\* The resident / student registration rate will be granted only after receipt of proof. The written proof of status (e.g. letter signed by the head of department confirming the status of the applicant / copy of student ID card) can be uploaded online during the registration process.

**Method of payment:**

Only credit cards (Visa, MasterCard, American Express) will be accepted. Bank transfers are only possible in exceptional cases for group bookings / hospitals. Please note that in payments by bank transfers, the bank charges must be paid by the delegate.

**On-site registration fee covers:**

- › Admission to on-site & virtual scientific sessions and satellite symposia
- › Admission to the on-site & virtual industrial exhibition
- › On-site coffee breaks and lunch to go
- › Congress bag
- › Opening ceremony
- › Certificate of attendance
- › Book of abstracts
- › Login to the on-demand area (session files will be available until October 20, 2024)

**Virtual registration fee covers:**

- › Admission to virtual streaming of scientific sessions and satellite symposia
- › Admission to virtual industrial exhibition
- › Virtual opening ceremony
- › Certificate of attendance
- › Book of abstracts
- › Login to the on-demand area (session files will be available until October 20, 2024)

**Registration Desk**

The registration desk is situated on the ground floor.

**Opening hours:**

Thursday, April 4	07:30–19:00
Friday, April 5	07:30–18:30
Saturday, April 6	08:00–14:00

**Smoking**

Smoking is strictly forbidden within the congress center.

**Social Networks**

Stay tuned and connected and follow the conference on Instagram and Facebook.



Facebook: <https://www.facebook.com/eadomelanoma/>

Instagram: [https://www.instagram.com/eado\\_melanoma/](https://www.instagram.com/eado_melanoma/)

### Speaker Preview Room

A Speakers' Preview Room is provided for all speakers. All presentations must be handed in the Speakers' Preview Room beforehand, as the presentations will be sent directly to the meeting room through the internal computer network.

**The following facilities will be provided in the room:** computers (Windows operating system) to review, alter and upload the presentations to the server and support by technical staff.

The presentations should be handed into the Speakers' Preview Room **at least two hours before the session**. Speakers with a presentation during the first time slot of the morning are kindly asked to hand in their presentation the day before. All speakers will be able to find their presentations easily on the preview monitor on the lectern in the corresponding session room.

### Sustainability

Sustainability is more important today than ever before. We are working internally on increasing our sustainability efforts and would like to encourage all involved in the 20<sup>th</sup> EADO Congress to minimize their environmental and social impacts. Go Green – Acting today for tomorrow!

#### Ways to get involved:

- › Travel by train/by carbon offsetting your flights to Paris and encourage your colleagues to do the same
- › Use the recycling bins provided on-site
- › Recycle your name-badge in the bin provided at the registration desk
- › Recycle all brochures and promotional items not needed in the bin provided within the industrial exhibition
- › Use the public transportation system in Paris.

### Welcome Reception

All registered delegates are invited to join the welcome reception on **Thursday, April 4, 2024** from 18:15–19:30 which will be held within the exhibition area. The Welcome Reception is open to all registered delegates, sponsors and exhibitors.

### Time Zone

Paris is in the Central European Time Zone which is 1 hour ahead of Greenwich Mean Time (GMT +1). Like most states in Europe, Paris observes daylight saving (summer time). On Sunday, March 31, 2024 time will be shifted forward by 1 hour (GMT+2).

### Weather

In April, the temperatures during the day in Paris range between 8°C and 17°C. However, the daily average temperature for Paris during April is around 13°C.

### WIFI

Free WIFI will be available within the congress area. The login details are as following:

**Network: EADO2024**

**Password: PARIS2024**



Thursday, April 4<sup>th</sup>, 2024

	<b>Amphithéâtre Richelieu</b> (1,000 seats, Level +1)	<b>Lulli</b> (220 seats, Level -1)	<b>Colbert</b> (100 seats, Level +2)	<b>Boileau</b> (50 seats, Level +2)
08:00–10:30	<b>Dermatoscopy Course</b> Basics and what's new	<b>Oncology Course</b> Basic questions in oncology	<b>Skin Care in Organ Transplant Patients Europe (SCOPE)</b>	<b>New Imaging Techniques</b>
10:30–10:45	Coffee Break + Exhibition Visit			
10:45–11:00	Opening Ceremony			
11:00–11:30	<b>Keynote Lecture 1</b> Old and new biomarkers in melanoma			
11:30–12:00	<b>Keynote Lecture 2</b> Spitzoid Tumors			
12:00–13:00	<b>Satellite Symposium 1</b>			
13:00–13:30	Lunch Break + Exhibition Visit + Poster Viewing			
13:30–14:00	<b>Keynote Lecture 3</b> What is new in NMSC			
14:00–15:00	<b>Satellite Symposium 2</b>			
15:00–16:00	<b>Symposium 1</b> New therapies 1 Vaccines	<b>Symposium 2</b> Medical messages for photoprotection	<b>Symposium 3</b> Biopsies, margins and second excision	<b>Symposium 4</b> cutaneous drug toxicities
16:00–16:30	Coffee Break + Exhibition Visit + Poster Viewing			
16:30–17:30	<b>Symposium 5</b> New therapies 2 Cellular therapies and T-Cell Engager	<b>Symposium 6</b> How to cooperate efficiently with your radiotherapists?	<b>Symposium 7</b> Management of actinic keratoses and field cancerization	
17:30–18:10				
18:15–19:30	Welcome Reception – Registration & Exhibition Area			

**Friday, April 5<sup>th</sup>, 2024**

	<b>Amphithéâtre Richelieu</b> (1,000 seats, Level +1)	<b>Lulli</b> (220 seats, Level -1)	<b>Colbert</b> (100 seats, Level +2)	<b>Boileau</b> (50 seats, Level +2)
08:00–09:30	<b>Symposium 8</b> New therapies 3 Antibody drug conjugates	<b>Symposium 9</b> Melanocytic nevi: biology and management	<b>Symposium 10</b> Guidelines for BCC and SCC	<b>Free Communications 1</b> Melanoma diagnosis and treatment
09:30–10:30	<b>Symposium 11</b> New therapies 4 New chemical drugs	<b>Symposium 12</b> The entire integument as a diagnostic target.	<b>Symposium 13</b> Challenging cases in skin cancer	
10:30–11:00	Coffee Break + Exhibition Visit + Poster Viewing			
11:00–11:30	<b>Keynote Lecture 4</b> Cellular therapies, vaccines, chemical drugs: what is the future?			
11:30–12:00	<b>Keynote Lecture 5</b> The development of skin cancer surgery			
12:00–13:00	<b>Satellite Symposium 3</b>			
13:00–13:30	Lunch Break + Exhibition Visit + Poster Viewing			
13:30–14:00	<b>Keynote Lecture 6</b> The microbiome in immunotherapy			
14:00–15:00	<b>Satellite Symposium 4</b>			
15:00–15:30	<b>Satellite Symposium 5</b>	<b>Symposium 14</b> Gene expression profiling assays and similar biomarkers	<b>Satellite Symposium 6</b>	<b>Symposium 15</b> Merkel cell carcinoma
15:30–16:00			<b>Satellite Symposium 7</b>	
16:00–16:30	Coffee Break + Exhibition Visit + Poster Viewing			
16:30–17:30	<b>Symposium 16</b> Controversies in SLNB and metastasectomy	<b>Satellite Symposium 8</b>	<b>Symposium 17</b> Management of rare malignant skin tumors	<b>Free Communications 2</b> Non-melanoma skin cancer diagnosis and treatment I (BCC and SCC)

**Saturday, April 6<sup>th</sup>, 2024**

	<b>Amphithéâtre Richelieu</b> (1,000 seats, Level +1)	<b>Lulli</b> (220 seats, Level -1)	<b>Colbert</b> (100 seats, Level +2)	<b>Boileau</b> (50 seats, Level +2)
09:00–10:00	<b>Symposium 18</b> Promises and limitations of intralesional treatments	<b>Symposium 19</b> Uveal and mucosal melanoma	<b>Symposium 20</b> Cutaneous lymphomas: from diagnosis to treatment	<b>Free Communications 3</b> Basic research, genetics and epidemiology of skin cancer
10:00–11:00	<b>Symposium 21</b> Management of non-cutaneous immune related adverse events	<b>Symposium 22</b> Management of melanoma brain metastasis	<b>Symposium 23</b> Skin Cancer in the immunosuppressed patient	<b>Free Communications 4</b> Non-melanoma skin cancer diagnosis and treatment II (lymphoma, merkel, sarcoma, etc.)
11:00–11:20	Coffee Break + Exhibition Visit + Poster Viewing			
11:20–11:30	<b>Poster &amp; Oral Communication Awards</b>			
11:30–12:00	<b>Keynote Lecture 7</b> Neoadjuvant treatment: current and future developments			
12:00–12:30	<b>Keynote Lecture 8</b> How to treat melanoma brain metastasis			
12:30–12:45	Closing Ceremony			





**SCIENTIFIC  
PROGRAM**

**Thursday, April 4<sup>th</sup>, 2024**

**Friday, April 5<sup>th</sup>, 2024**

**Saturday, April 6<sup>th</sup>, 2024**

## Thursday, April 4<sup>th</sup>, 2024

<b>Amphithéâtre Richelieu</b> (1,000 seats, Floor +1)	<b>Lulli</b> (220 seats, Level -1)
<p><b>08:00–10:30</b></p> <p><b>Dermatoscopy Course</b>  <b>Basics and what's new</b>  <i>Chairs: Giuseppe Argenziano, Naples, Italy</i>  <i>Aimilos Lallas, Thessaloniki, Greece</i>  <i>Iris Zalaudek, Trieste, Italy</i></p>	<p><b>08:00–10:30</b></p> <p><b>Oncology Course</b>  <b>Basic questions in oncology</b>  <i>Chairs: Veronique Bataille, London, United Kingdom</i>  <i>Christoph Höller, Vienna, Austria</i>  <i>Olivier Michielin, Geneva, Switzerland</i>  <i>Benedicte Oules, Paris, France</i></p>
<p><b>08:00–08:20</b>  <b>Small diameter melanoma – only over diagnosis?</b>  <i>Aimilos Lallas, Thessaloniki, Greece</i></p>	<p><b>08:00–08:05</b>  <b>Welcome and introduction</b></p>
<p><b>08:30–08:50</b>  <b>Defining urgency for surgery – are all melanomas an urgency?</b>  <i>Giuseppe Argenziano, Naples, Italy</i></p>	<p><b>08:05–08:25</b>  <b>Identifying family cancer syndromes. When is germline genetic testing helpful?</b>  <i>Veronique Bataille, London, United Kingdom</i></p>
<p><b>09:00–09:20</b>  <b>Follow up after melanoma diagnosis – lifelong surveillance?</b>  <i>Iris Zalaudek, Trieste, Italy</i></p>	<p><b>08:30–08:50</b>  <b>Principles of targeted therapies</b>  <i>Christoph Hoeller, Wien, Austria</i></p>
<p><b>09:30–09:50</b>  <b>From a vision to a mission: how may screening look like in 2034?</b>  <i>Josep Malvehy, Barcelona, Spain</i></p>	<p><b>09:00–09:20</b>  <b>Principles of immunotherapies</b>  <i>Caroline Robert, Paris, France</i></p>
<p><b>10:00–10:20</b>  <b>Can we predict biology by morphology?</b>  <i>Susana Puig, Barcelona, Spain</i></p>	<p><b>09:30–09:50</b>  <b>Resistance mechanisms</b>  <i>Benedict Oule, Paris, France</i></p>
	<p><b>10:00–10:20</b>  <b>Biomarkers for patient selection</b>  <i>Olivier Michielin, Geneva, France</i></p>

<p style="text-align: center;"><b>Colbert</b> (100 seats, Level +2)</p>	<p style="text-align: center;"><b>Boileau</b> (50 seats, Level +2)</p>
<p><b>08:00–10:30</b></p> <p><b>Skin Care in Organ Transplant Patients Europe (SCOPE)</b> <i>Chairs: Alexandra Geusau, Vienna, Austria Ulrike Leiter-Stöppke, Tuebingen, Germany</i></p>	<p><b>08:00–10:30</b></p> <p><b>New Imaging Techniques</b> <i>Chairs: Barouyr Baroudjian, Paris, France Mariano Suppa, Brussels, Belgium Julia Welzel, Augsburg, Germany</i></p>
<p><b>08:00–08:05</b> <b>Welcome and introduction</b> <i>Alexandra Geusa, Vienna, Austria</i></p>	<p><b>08:00–08:17</b> <b>The current landscape of non-invasive skin imaging techniques</b> <i>Elisa Cinotti, Siena, Italy</i></p>
<p><b>08:05–08:25</b> <b>Exploring the risk and therapeutic implications of non-OTR immunosuppression in cutaneous squamous cell carcinoma management (including Q&amp;A)</b> <i>Emily Ruiz, Boston, USA</i></p>	<p><b>08:22–08:39</b> <b>In-vivo confocal microscopy</b> <i>Caterina Longo, Modena, Italy</i></p>
<p><b>08:25–08:55</b> <b>How to set up a Speciality clinic for the dermatologic care of solid-organ transplant recipients' (including Q&amp;A)</b> <i>Elsemieke Plasmeijer, Amsterdam, The Netherlands</i></p>	<p><b>08:44–09:01</b> <b>Ex-vivo confocal microscopy</b> <i>Javiera Perez-Anker, Barcelona, Spain</i></p>
<p><b>08:55–09:15</b> <b>Skin cancer in HIV (including Q&amp;A)</b> <i>Christopher Bunker, London, United Kingdom</i></p>	<p><b>09:06–09:23</b> <b>Line-field confocal optical coherence tomography (LC-OCT)</b> <i>Mariano Suppa, Brussels, Belgium</i></p>
<p><b>09:15–09:45</b> <b>The role of cHPV in cSCC development: culprit or innocent? – Are cHPV causal co-factors in cSCC development or commensal microorganisms of the skin that protect against skin cancer</b> <i>Ingo Nindl, Berlin, Germany</i></p>	<p><b>09:28–09:45</b> <b>Integration of artificial intelligence into LC-OCT and OCT for skin cancer imaging</b> <i>Julia Welzel, Augsburg, Germany</i></p>
<p><b>09:45–10:00</b> <b>Rates of second tumor, metastasis and death from cSCC in patients with and without transplant associated immunosuppression (including Q&amp;A)</b> <i>Petter Gjersvik, Oslo, Norway</i></p>	<p><b>09:50–10:07</b> <b>LC OCT for genital pigmented lesions and lentigo maligna</b> <i>Barouyr Baroudjian, Paris, France</i></p>
	<p><b>10:12–10:30</b> <b>(Ultra) high-frequency ultrasound for skin cancer</b> <i>Philippe Bahadoran, Nice, France</i></p>

# Thursday, April 4<sup>th</sup>, 2024

<b>Amphithéâtre Richelieu</b> (1,000 seats, Floor +1)	<b>Lulli</b> (220 seats, Level -1)
--	---------------------------------------

<b>10:30–10:45</b> Coffee Break + Exhibition Visit	
<b>10:45–11:00</b> Opening Ceremony	
<b>11:00–11:30</b>	
<b>Keynote Lecture 1</b> <i>Chair: Olivier Michielin, Geneva, Switzerland</i>  <b>Old and new biomarkers in melanoma</b> <i>Caroline Robert, Paris, France</i>	
<b>11:30–12:00</b>	
<b>Keynote Lecture 2</b> <i>Chair: Caterina Longo, Modena, Italy</i>  <b>Spitzoid tumors</b> <i>Aimilios Lallas, Thessaloniki, Greece</i>	
<b>12:00–13:00</b>	
<b>Satellite Symposium 1</b>	
<b>13:00–13:30</b> Coffee Break + Exhibition Visit + Poster Viewing	
<b>13:30–14:00</b>	
<b>Keynote Lecture 3</b> <i>Chair: Ulrike Leiter-Stöppke, Tuebingen, Germany</i>  <b>What is new in NMSC</b> <i>Axel Hauschild, Kiel, Germany</i>	
<b>14:00–15:00</b>	
<b>Satellite Symposium 2</b>	

<b>Colbert</b> (100 seats, Level +2)	<b>Boileau</b> (50 seats, Level +2)
<p><b>10:00–10:25</b>  <b>Tumour Board and expert panel discussion: difficult to treat cases</b>  <i>Chairs:</i>  <i>Catherine Harwood, London, United Kingdom</i>  <i>Mirjam Nägeli, Zurich, Switzerland</i></p> <p><i>Case presentations by:</i>  <i>Glenn Geidel, Hamburg, Germany</i>  <i>Mirjam Nägeli, Zurich, Switzerland</i>  <i>Carla Ferrándiz-Pulido, Barcelona, Spain</i></p> <p><b>10:25–10:30</b>  <b>Closing remarks</b>  <i>Alexandra Geusau, Vienna, Austria</i>  <i>Ulrike Leiter-Stöppke, Tuebingen, Germany</i></p>	

## Thursday, April 4<sup>th</sup>, 2024

<b>Amphithéâtre Richelieu</b> (1,000 seats, Floor +1)	<b>Lulli</b> (220 seats, Level -1)
<p><b>15:00–16:00</b></p> <p><b>Symposium 1</b>  <b>New therapies 1</b>  <b>Vaccines</b>  <i>Chairs: Brigitte Dréno, Nantes, France</i>  <i>Lukas Flatz, Tuebingen, Germany</i></p> <p><b>15:00–15:12</b>  <b>mRNA vaccines and combination with ICI</b>  <i>Lukas Flatz, Tuebingen, Germany</i></p> <p><b>15:15–15:27</b>  <b>Neoantigen vaccines</b>  <i>Omar Hasan Ali, Zurich, Switzerland</i></p> <p><b>15:30–15:42</b>  <b>Targeting melanocytic lineage antigens – hopes and challenges</b>  <i>Tobias Bald, Bonn, Germany</i></p> <p><b>15:45–15:57</b>  <b>Dendritic cell vaccines and vaccination with oncolytic viruses</b>  <i>Brigitte Dréno, Nantes, France</i></p>	<p><b>15:00–16:00</b></p> <p><b>Symposium 2</b>  <b>Medical messages for photoprotection</b>  <i>Chairs: Veronique del Marmol, Brussels, Belgium</i>  <i>Susana Puig, Barcelona, Spain</i></p> <p><b>15:00–15:12</b>  <b>How to improve awareness in skin cancer</b>  <i>Veronique del Marmol, Brussels, Belgium</i></p> <p><b>15:15–15:27</b>  <b>Current recommendations for UV protection</b>  <i>Lieve Brochez, Gent, Belgium</i></p> <p><b>15:30–15:42</b>  <b>Professional and recreational photoprotection. Same or different messages?</b>  <i>Susana Puig, Barcelona, Spain</i></p> <p><b>15:45–15:57</b>  <b>Photoprotection habits in Europe: Euromelanoma measures</b>  <i>Katarina Wunderlich, Wuppertal, Germany</i></p>
<p><b>16:00–16:30</b> Coffee Break + Exhibition Visit + Poster Viewing</p>	



		<b>Boileau</b> (50 seats, Level +2)
<p><b>Colbert</b> (100 seats, Level +2)</p> <p><b>15:00–16:00</b></p> <p><b>Symposium 3</b>  <b>Biopsies, margins and second excision</b>  <i>Chairs: Ralf Gutzmer, Minden, Germany</i>  <i>Roland Kaufmann, Frankfurt, Germany</i></p> <p><b>15:00–15:12</b>  <b>New imaging techniques in pre-operative margin assessment</b>  <i>Caterina Longo, Modena, Italy</i></p> <p><b>15:15–15:27</b>  <b>Special aspect and particularities in skin cancer biopsies</b>  <i>Roland Kaufmann, Frankfurt, Germany</i></p> <p><b>15:30–15:42</b>  <b>Excision margins – current and future role in skin cancer</b>  <i>Ralf Gutzmer, Minden, Germany</i></p> <p><b>15:45–15:57</b>  <b>Defect repair in second excisions – my personal favorites</b>  <i>Ricardo Viera, Coimbra, Portugal</i></p>		<p><b>15:00–16:00</b></p> <p><b>Symposium 4</b>  <b>Cutaneous drug toxicities</b>  <i>Chairs: Andrea Forschner, Tuebingen, Germany</i>  <i>Vincent Sibaud, Toulouse, France</i></p> <p><b>15:00–15:01</b>  <b>Introduction: dermatology for cancer patients</b>  <i>Vincent Sibaud, Toulouse, France</i></p> <p><b>15:01–15:15</b>  <b>Dermatological toxicities of immune checkpoint inhibitors</b>  <i>Aimilos Lallas, Thessaloniki, Greece</i></p> <p><b>15:20–15:35</b>  <b>Dermatological toxicities of Tebentafusp</b>  <i>Andrea Forschner, Tuebingen, Germany</i></p> <p><b>15:40–15:55</b>  <b>Dermatological toxicities of emergent therapies</b>  <i>Vincent Sibaud, Toulouse, France</i></p>

## Thursday, April 4<sup>th</sup>, 2024

<b>Amphithéâtre Richelieu</b> (1,000 seats, Floor +1)	<b>Lulli</b> (220 seats, Level -1)
<b>16:30–18:10</b>	<b>16:30–17:30</b>
<b>Symposium 5</b> New therapies 2 Cellular therapies and T-Cell Engager <i>Chairs: John Haanen, Amsterdam, The Netherlands</i> <i>Sophie Piperno-Neumann, Paris, France</i>	<b>Symposium 6</b> How to cooperate efficiently with your radiotherapists? <i>Chairs: Hussein Tawbi, Houston, United States</i> <i>Philippe Saiag, Versailles, France</i>
<b>16:30–16:45</b> Talk on tebentafusp for uveal melanoma <i>Sophie Piperno-Neumann, Paris, France</i>	<b>16:30–16:45</b> How does the medical treatment of skin cancer cooperate efficiently with radiotherapy? <i>Philippe Saiag, Paris, France</i>
<b>16:50–17:05</b> Talk on TIL for melanoma (skin, uveal and mucosal) <i>John Haanen, Amsterdam, The Netherlands</i>	<b>16:50–17:05</b> How the radiation oncologist can help the dermatologist in 2024? <i>Pierre Loap, Paris, France</i>
<b>17:10–17:25</b> Talk on other T-Cell engagers incl. PRAME Imtec <i>Victor Moreno, Madrid, Spain</i>	<b>17:10–17:25</b> How can we treat brain metastases from skin cancer with radiosurgery in 2024? <i>Charles Valery, Paris, France</i>
<b>17:30–17:45</b> Talk on TCR-T covering MAGE antigens and PRAME <i>Paul Nathan, Northwood, United Kingdom</i>	
<b>17:50–18:05</b> Gene modified cell therapies for melanoma <i>Victor Moreno, Madrid, Spain</i>	
<b>18:15–19:30 Welcome Reception – Registration &amp; Exhibition Area</b>	

<p style="text-align: center;"><b>Colbert</b> (100 seats, Level +2)</p>	<p style="text-align: center;"><b>Boileau</b> (50 seats, Level +2)</p>
<p><b>16:30–17:30</b></p> <p><b>Symposium 7</b>  <b>Management of actinic keratoses and field cancerization</b>  <i>Chairs: Maria Concetta Fagnoli, L'Aquila, Italy</i>  <i>Lidija Kandolf, Belgrade, Serbia</i></p> <p><b>16:30–16:42</b>  <b>Actinic keratosis and field cancerization: definition and diagnosis</b>  <i>Maria Concetta Fagnoli, L'Aquila, Italy</i></p> <p><b>16:45–16:57</b>  <b>Factors that influence treatment decision</b>  <i>Lidija Kandolf, Belgrade, Serbia</i></p> <p><b>17:00–17:12</b>  <b>Non-surgical treatment options for actinic keratosis</b>  <i>Klara Mosterd, Maastricht, The Netherlands</i></p> <p><b>17:15–17:27</b>  <b>Tailored treatment for AK patients</b>  <i>Nicole Kellener-Smeets, Maastricht, The Netherlands</i></p>	

## Friday, April 5<sup>th</sup>, 2024

<b>Amphithéâtre Richelieu</b> (1,000 seats, Floor +1)	<b>Lulli</b> (220 seats, Level -1)
<p><b>08:00–09:30</b></p> <p><b>Symposium 8</b>  <b>New therapies 3</b>  <b>Antibody drug conjugates</b>  <i>Chairs: Thomas Eigentler, Berlin, Germany</i>  <i>Mahtab Samimi, Tours, France</i></p>	<p><b>08:00–09:30</b></p> <p><b>Symposium 9</b>  <b>Melanocytic nevi: biology and management</b>  <i>Chairs: Giuseppe Argenziano, Naples, Italy</i>  <i>Arnaud de la Fouchardière, Lyon, France</i></p>
<p><b>08:00–08:17</b>  <b>Principles of ADC / bispecific antibodies</b>  <i>Dario Neri, Zurich, Switzerland</i></p>	<p><b>08:00–08:15</b>  <b>Congenital nevi</b>  <i>Arnaud de la Fouchardière, Lyon, France</i></p>
<p><b>08:22–08:39</b>  <b>ADC in melanoma and cutaneous squamous cell carcinoma</b>  <i>Thomas Eigentler, Berlin, Germany</i></p>	<p><b>08:18–08:33</b>  <b>Acquired nevi</b>  <i>Michele Donati, Rome, Italy</i></p>
<p><b>08:44–09:01</b>  <b>ADC in Merkel Cell Carcinoma</b>  <i>Mahtab Samimi, Tours, France</i></p>	<p><b>08:36–08:51</b>  <b>Blue nevi</b>  <i>Arnaud de la Fouchardière, Lyon, France</i></p>
<p><b>09:06–09:23</b>  <b>ADC in cutaneous lymphomas</b>  <i>Adèle de Masson, Paris, France</i></p>	<p><b>08:54–09:09</b>  <b>Spitz nevi</b>  <i>Giuseppe Argenziano, Naples, Italy</i></p>
	<p><b>09:12–09:27</b>  <b>Special nevi</b>  <i>Aimilios Lallas, Thessaloniki, Greece</i></p>

<p style="text-align: center;"><b>Colbert</b> (100 seats, Level +2)</p>	<p style="text-align: center;"><b>Boileau</b> (50 seats, Level +2)</p>
<p><b>08:00–09:30</b></p> <p><b>Symposium 10</b>  <b>Guidelines for BCC and SCC</b>  <i>Chairs: Ketty Peris, Rome, Italy</i>  <i>Alexander Stratigos, Athens, Greece</i></p> <hr/> <p><b>08:00–08:17</b>  <b>Easy to treat BCC</b>  <i>Klara Mosterd, Maastricht, The Netherlands</i></p> <p><b>08:22–08:39</b>  <b>Difficult to treat BCC</b>  <i>Maria Concetta Fargnoli, L'Aquila, Italy</i></p> <p><b>08:44–09:01</b>  <b>Easy to treat cSCC</b>  <i>David Moreno-Ramirez, Seville, Spain</i></p> <p><b>09:06–09:23</b>  <b>Difficult to treat cSCC</b>  <i>Clio Dessinioti, Athens, Greece</i></p>	<p><b>08:00–09:10</b></p> <p><b>Free Communications 1</b>  <b>Melanoma diagnosis and treatment</b>  <i>Chairs: Stephane Dalle, Lyon, France</i>  <i>Caroline Dutriaux, Bordeaux, France</i>  <i>Henri Montaudié, Nice, France</i></p> <hr/> <p><b>08:00–08:07</b>  <b>Does the interval between melanoma diagnosis and surgery have an impact on outcomes? A systematic review and meta-analysis.</b>  <i>Anna Elizabete Strazda, Cambridge, Great Britain</i></p> <p><b>08:10–08:17</b>  <b>Use of 3-dimensional total body photography and digital dermoscopy with artificial intelligence algorithms for early melanoma detection in high-risk patients</b>  <i>Laura Serra-García, Barcelona, Spain</i></p> <p><b>08:20–08:27</b>  <b>Unlocking Potential in Clinical Practice: A Comprehensive Assessment of an Artificial Intelligence Based Clinical Decision Support System for Cutaneous Melanoma Detection</b>  <i>Haleh Davanian, Stockholm, Sweden</i></p> <p><b>08:30–08:37</b>  <b>Nationwide study of the treatment options of lentigo maligna and recurrence rates in the Netherlands</b>  <i>Judith Zoutendijk, Rotterdam, The Netherlands</i></p> <p><b>08:40–08:47</b>  <b>Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition</b>  <i>George Lyrarakis, Athens, Greece</i></p>

# Friday, April 5<sup>th</sup>, 2024

<b>Amphithéâtre Richelieu</b> (1,000 seats, Floor +1)	<b>Lulli</b> (220 seats, Level -1)
--	---------------------------------------

<b>09:30–10:30</b>	<b>09:30–10:30</b>
<b>Symposium 11</b> <b>New therapies 4</b> <b>New chemical drugs</b> <i>Chairs: Nicolas Dumaz, Paris, France</i> <i>Brigitte Dréno, Paris, France</i>	<b>Symposium 12</b> <b>The entire integument as a diagnostic target</b> <i>Chairs: Caroline Gaudy-Marqueste, Marseille, France</i> <i>Josep Malvehy, Barcelona, Spain</i>
<b>09:30–09:45</b> <b>Developments of MEKi/BRAFi/NRAS inhibitors combinations</b> <i>Reinhard Dummer, Zurich, Switzerland</i>	<b>09:30–09:45</b> <b>2D and 3D Total Body Photography for high-risk melanoma patients: state of the art in clinical practice</b> <i>Caroline Gaudy-Marqueste, Marseille, France</i> <i>Jilliana Monnier, Marseille, France</i>
<b>09:50–10:05</b> <b>PI3K/ErbB3, c-Kit, NTRK inhibitors</b> <i>Nicolas Dumaz, Paris, France</i>	<b>09:50–10:05</b> <b>AI for the detection of skin cancer using Total Body Photography and dermoscopy: fiction or reality?</b> <i>Konstantinos Liopyris, Athens, Greece</i>
<b>10:10–10:25</b> <b>PDE4 inhibitors for melanoma treatment</b> <i>Nicolas Dumaz, Paris, France</i>	<b>10:10–10:25</b> <b>Deep imaging for biomarker discovery in skin cancer</b> <i>Josep Malvehy, Barcelona, Spain</i>

**10:30–11:00** Coffee Break + Exhibition Visit + Poster Viewing

<p style="text-align: center;"><b>Colbert</b> (100 seats, Level +2)</p>	<p style="text-align: center;"><b>Boileau</b> (50 seats, Level +2)</p>
<p><b>09:30–10:30</b></p> <p><b>Symposium 13</b>  <b>Challenging cases in skin cancer</b>  <i>Chairs: Ana-Maria Forsea, Bucharest, Romania</i>  <i>Nicole Kelleners-Smeets</i>  <i>Maastricht, The Netherlands</i></p> <p><b>09:30–09:42</b>  <b>Challenging cases from the perspective of the dermato-surgeon</b>  <i>David Moreno-Ramirez, Seville, Spain</i></p> <p><b>09:45–09:57</b>  <b>Challenges of skin cancers in Asians</b>  <i>Hisashi Uhara, Sapporo, Japan</i></p> <p><b>10:00–10:12</b>  <b>Challenging cases: NMSC</b>  <i>Nicole Kelleners-Smeets, Maastricht, The Netherlands</i></p> <p><b>10:15–10:27</b>  <b>Challenging cases: melanoma</b>  <i>Ana-Maria Forsea, Bucharest, Romania</i></p>	<p><b>08:50–08:57</b>  <b>Early recurrence in a pooled international cohort of melanoma patients treated with adjuvant nivolumab in a real-world setting</b>  <i>Stéphane Dalle, Lyon, France</i></p> <p><b>09:00–09:07</b>  <b>Successful implementation of handheld reflectance confocal microscopy as the standard of care in the (surgical) management of lentigo maligna (melanoma)</b>  <i>Yannick Elshot, Amsterdam, The Netherlands</i></p>

## Friday, April 5<sup>th</sup>, 2024

<b>Amphithéâtre Richelieu</b> (1,000 seats, Floor +1)	<b>Lulli</b> (220 seats, Level -1)
<b>11:00–11:30</b>	
<b>Keynote Lecture 4</b> <i>Chair: Céleste Lebbé, Paris, France</i>  <b>Cellular therapies, vaccines, chemical drugs: what is the future?</b> <i>John Haanen, Amsterdam, The Netherlands</i>	
<b>11:30–12:00</b>	
<b>Keynote Lecture 5</b> <i>Chair: Claus Garbe, Tuebingen, Germany</i>  <b>The development of skin cancer surgery</b> <i>Alexander Eggermont, Utrecht, The Netherlands</i>	
<b>12:00–13:00</b>	
<b>Satellite Symposium 3</b>	
<b>13:00–13:30</b> Lunch Break + Exhibition Visit + Poster Viewing	
<b>13:30–14:00</b>	
<b>Keynote Lecture 6</b> <i>Chair: Dirk Schadendorf, Essen, Germany</i>  <b>The microbiome in immunotherapy</b> <i>Laurence Zitvogel, Paris, France</i>	
<b>14:00–15:00</b>	
<b>Satellite Symposium 4</b>	



**Colbert**  
(100 seats, Level +2)

**Boileau**  
(50 seats, Level +2)

## Friday, April 5<sup>th</sup>, 2024

<b>Amphithéâtre Richelieu</b> (1,000 seats, Floor +1)	<b>Lulli</b> (220 seats, Level -1)
<p><b>15:00–16:00</b></p> <p><b>Satellite Symposium 5</b></p>	<p><b>15:00–16:00</b></p> <p><b>Symposium 14</b>            Gene expression profiling assays and similar biomarkers  <i>Chairs: Teresa Amaral, Tuebingen, Germany</i>  <i>Dirk Schadendorf, Essen, Germany</i></p> <p><b>15:00–15:15</b>            Biomarker – ready for prime time: an introduction  <i>Ivan Marquez-Rodas, Madrid, Spain</i></p> <p><b>15:20–15:35</b>            Overview gene expression profiles – where, when and how?  <i>Teresa Amaral, Tuebingen, Germany</i></p> <p><b>15:40–15:55</b>            Utility of immunohistochemical assay systems  <i>Dirk Schadendorf, Essen, Germany</i></p>
<p><b>16:00–16:30</b> Coffee Break + Exhibition Visit + Poster Viewing</p>	
<p><b>16:30–17:30</b></p> <p><b>Symposium 16</b>            Should sentinel lymph node biopsy remain part of the AJCC classification?  <i>Chairs: David Moreno-Ramirez, Seville, Spain</i>  <i>Ricardo Vieira, Coimbra, Portugal</i></p> <p><b>16:30–16:50</b>            Yes  <i>Roland Kaufmann, Frankfurt, Germany</i></p> <p><b>16:50–17:10</b>            No  <i>Alexander Eggermont, Utrecht, The Netherlands</i></p> <p><b>17:10–17:30</b>            Discussion</p>	<p><b>16:30–17:30</b></p> <p><b>Satellite Symposium 8</b></p>

<p style="text-align: center;"><b>Colbert</b> (100 seats, Level +2)</p>	<p style="text-align: center;"><b>Boileau</b> (50 seats, Level +2)</p>
<p><b>15:00–15:30</b></p> <p><b>Satellite Symposium 6</b></p> <hr/> <p><b>15:30–16:00</b></p> <p><b>Satellite Symposium 7</b></p>	<p><b>15:00–16:00</b></p> <p><b>Symposium 15</b> <b>Merkel cell carcinoma</b> <i>Chairs: Jürgen C. Becker, Essen and Heidelberg, Germany</i> <i>Astrid Blom, Boulogne, France</i></p> <hr/> <p><b>15:00–15:15</b> <b>Molecular pathology of MCC</b> <i>Axel zur Hausen, Maastricht, The Netherlands</i></p> <hr/> <p><b>15:20–15:35</b> <b>Currently established management of MCC</b> <i>Astrid Blom, Boulogne, France</i></p> <hr/> <p><b>15:40–15:55</b> <b>Future possibilities for the management of MCC</b> <i>Jürgen C. Becker, Essen and Heidelberg, Germany</i></p>
<p><b>16:30–17:20</b></p> <p><b>Symposium 17</b> <b>Management of rare malignant skin tumors</b> <i>Chairs: Petr Arenberger, Prague, Czech Republic</i> <i>Anne Pham Ledard, Bordeaux, France</i></p> <hr/> <p><b>16:30–16:42</b> <b>Overview on rare skin tumors</b> <i>Petr Arenberger, Prague, Czech Republic</i></p> <hr/> <p><b>16:45–17:02</b> <b>Difficult to treat Merkel cell carcinoma</b> <i>Mahtab Samimi, Tours, France</i></p> <hr/> <p><b>17:05–17:17</b> <b>Squamous cell carcinoma as a rare but challenging comorbidity of hidradenitis suppurativa</b> <i>Monika Arenbergerova, Prague, Czech Republic</i></p>	<p><b>16:30–17:40</b></p> <p><b>Free Communications 2</b> <b>Non-melanoma skin cancer diagnosis and treatment I (BCC and SCC)</b> <i>Chairs: Eve Maubec, Paris, France</i> <i>Charlée Nardin, Besançon, France</i> <i>Cécile Pagès, Toulouse, France</i></p> <hr/> <p><b>16:30–16:37</b> <b>Characterization of 10 cutaneous tumors with ex vivo LC-OCT: A novel tool in dermatological surgery with margin control?</b> <i>Pau Rosés-Gibert, Barcelona, Spain</i></p> <hr/> <p><b>16:40-16:47</b> <b>A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti-PD-1/ L1-experienced cutaneous squamous cell carcinoma</b> <i>Matthew Fury, Tarrytown, United States</i></p>

# Friday, April 5<sup>th</sup>, 2024

<b>Amphithéâtre Richelieu</b> (1,000 seats, Floor +1)	<b>Lulli</b> (220 seats, Level -1)
--	---------------------------------------

<b>Colbert</b> (100 seats, Level +2)	<b>Boileau</b> (50 seats, Level +2)
	<p><b>16:50–16:57</b>  <b>The treatment of elderly patients with locally advanced or metastatic cutaneous squamous cell carcinoma using Cemiplimab monotherapy or Cemiplimab associated with palliative radiotherapy: A single centre experience from the United Kingdom.</b>  <i>Alan del Carpio Barreda, Cottingham, Great Britain</i></p> <p><b>17:00–17:07</b>  <b>The Dutch Keratinocyte Cancer Collaborative: real-world linked health care data to identify and follow-up patients with advanced cutaneous squamous carcinoma on a nationwide level</b>  <i>Marlies Wakkee, Rotterdam, The Netherlands</i></p> <p><b>17:10–17:17</b>  <b>Integrating a Clinicopathological Risk Prediction Model into the European Guideline for Cutaneous Squamous Cell Carcinoma</b>  <i>Marlies Wakkee, Rotterdam, The Netherlands</i></p> <p><b>17:20–17:27</b>  <b>Cumulative sum analysis-integrated e-learning for differentiation between basal cell carcinoma and non-basal cell carcinoma on optical coherence tomography: a diagnostic cohort study</b>  <i>Tom Wolswijk, Maastricht, The Netherlands</i></p> <p><b>17:30–17:37</b>  <b>Neoadjuvant Vismodegib plus Mohs surgery for locally advanced periocular basal cell carcinoma. Real world scenario</b>  <i>Abel Gonzalez, Buenos Aires, Argentina</i></p>

## Saturday, April 6<sup>th</sup>, 2024

<b>Amphithéâtre Richelieu</b> (1,000 seats, Floor +1)	<b>Lulli</b> (220 seats, Level -1)
<p><b>09:00–10:00</b></p> <p><b>Symposium 18</b>            Promises and limitations of intralesional treatments  <i>Chairs: Reinhard Dummer, Zurich, Switzerland            Christoph Höller, Vienna, Austria</i></p>	<p><b>09:00–10:00</b></p> <p><b>Symposium 19</b>            Uveal and mucosal melanoma  <i>Chairs: Jessica Hassel, Heidelberg, Germany            Paul Lorigan, Manchester, United Kingdom</i></p>
<p><b>09:00–09:15</b>            neoBCC – A neoadjuvant, phase II trial of Talimogene laherparepvec in cutaneous basal cell carcinoma  <i>Christoph Höller, Vienna, Austria</i></p>	<p><b>09:00–09:10</b>            Immunotherapy for mucosal melanoma – adjuvant, neoadjuvant and advanced  <i>Paul Lorigan, Manchester, United Kingdom</i></p>
<p><b>09:20–09:35</b>            T-VEC in cutaneous lymphomas  <i>Egle Ramelyte, Zurich, Switzerland</i></p>	<p><b>09:15–09:25</b>            Emerging treatments for mucosal melanoma – from targeted to antiangiogenetic approaches  <i>Céleste Lebbé, Paris, France</i></p>
<p><b>09:40–09:55</b>            New developments in the intralesional therapy of skin cancers  <i>Caroline Robert, Paris, France</i></p>	<p><b>09:30–09:40</b>            Liver-directed therapies – pros and cons tbc  <i>Jessica Hassel, Heidelberg, Germany</i></p>
	<p><b>09:45–09:55</b>            Immunotherapy of uveal melanoma – standard of care and future  <i>Jessica Hassel, Heidelberg, Germany</i></p>

<p style="text-align: center;"><b>Colbert</b> (100 seats, Level +2)</p>	<p style="text-align: center;"><b>Boileau</b> (50 seats, Level +2)</p>
<p><b>09:00–10:00</b></p> <p><b>Symposium 20</b> Cutaneous lymphomas: from diagnosis to treatment <i>Chairs: Chalid Assaf, Krefeld, Germany</i> <i>Adele de Masson, Paris, France</i></p> <p><b>09:00–09:12</b> Early diagnosis of mycosis fungoides: does it make a difference? <i>Emmanuella Guenova, Geneva, Switzerland</i></p> <p><b>09:15–09:27</b> Role of combination therapy in cutaneous T-cell lymphoma (CTCL) <i>Chalid Assaf, Krefeld, Germany</i></p> <p><b>09:30–09:42</b> Treatment of cutaneous B-cell lymphoma, including novel compounds <i>Richard Cowan, Manchester, UK</i></p> <p><b>09:45–09:57</b> Role of allogeneic hematopoietic stem cell transplantation in CTCL <i>Adele de Masson, Paris, France</i></p>	<p><b>09:00–10:00</b></p> <p><b>Free Communications 3</b> Basic research, genetics and epidemiology of skin cancer <i>Chairs: Julie Delyon, Paris, France</i> <i>Nicolas Dumaz, Paris, France</i> <i>Samia Mourah, Paris, France</i></p> <p><b>09:00–09:07</b> Circulating tumor DNA: a promising biomarker in stage III BRAF+ melanoma <i>Gabriele Rocuzzo, Turin, Italy</i></p> <p><b>09:10–09:17</b> Is There a Distinctive Molecular Identity for Sinonasal Malignant Mucosal Melanoma Compared to Cutaneous Melanoma? <i>Manuel Molina-Garcia, Barcelona, Spain</i></p> <p><b>09:20–09:27</b> High dose Vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of randomized a double- blind, placebo-controlled study (ViDMe trial) <i>Julie De Smedt, Leuven, Belgium</i></p> <p><b>09:30–09:37</b> Identification of patients at high risk for relapse by Merlin Assay (CP-GEP) in an independent cohort of patients with melanoma who did not undergo sentinel lymph node biopsy: head and neck subgroup analysis <i>Teresa Amaral, Tuebingen, Germany</i></p> <p><b>09:40–09:47</b> Prognostic value of tumor microenvironment molecules in the response to immunotherapy in advanced melanoma <i>Laura Parra-Navarro, Barcelona, Spain</i></p> <p><b>09:50–09:57</b> RNA helicase DHX9 enables PBX1 mRNA translation by unfolding RNA G-quadruplex in melanoma <i>Yutong Sui, Changchun, China</i></p>

## Saturday, April 6<sup>th</sup>, 2024

<b>Amphithéâtre Richelieu</b> (1,000 seats, Floor +1)	<b>Lulli</b> (220 seats, Level -1)
<p><b>10:00–11:00</b></p> <p><b>Symposium 21</b>  <b>Management of non-cutaneous immune related adverse events</b>  <i>Chairs: Barouyr Baroudjian, Paris, France</i>  <i>Jessica Hassel, Heidelberg, Germany</i></p> <p><b>10:00–10:12</b>  <b>Immune-related toxicities and quality of life after adjuvant immunotherapy – seasonal variation and association with outcome</b>  <i>Eva Ellebaek, Copenhagen, Denmark</i></p> <p><b>10:15–10:27</b>  <b>Impact of aging and co-medication on immune-related adverse events</b>  <i>Florence Brunet Possenti, Paris, France</i></p> <p><b>10:30–10:42</b>  <b>Management of troponin elevation</b>  <i>Jessica Hassel, Heidelberg, Germany</i></p> <p><b>10:45–10:57</b>  <b>Neurological adverse events: when should we suspect them, how to diagnose them and how should we treat them</b>  <i>Stefania Cuzzubo, Paris, France</i></p>	<p><b>10:00–11:00</b></p> <p><b>Symposium 22</b>  <b>Special requirements for management of brain metastasis and leptomeningeal disease</b>  <i>Chairs: Friedegund Meier, Dresden, Germany</i>  <i>Hussein Tawbi, Houston, United States</i></p> <p><b>10:00–10:10</b>  <b>What are the recommendations of the melanoma guidelines for brain metastases today and tomorrow?</b>  <i>Reinhard Dummer, Zurich, Switzerland</i></p> <p><b>10:12–10:22</b>  <b>Alternative approaches to patients requiring corticosteroids</b>  <i>Nelson Moss, New York, United States</i></p> <p><b>10:24–10:34</b>  <b>The challenge of leptomeningeal disease: future directions</b>  <i>Isabella Glitza, Houston, United States</i></p> <p><b>10:36–10:46</b>  <b>Mutli-disciplinary care models and the evolution of Brain Metastases Clinics</b>  <i>Hussein Tawbi, Houston, United States</i></p> <p><b>10:48–10:58</b>  <b>The final frontier for melanoma brain metastasis</b>  <i>Friedegund Meier, Dresden, Germany</i></p>
<p><b>11:00–11:20</b> Break</p>	




<p style="text-align: center;"><b>Colbert</b> (100 seats, Level +2)</p>	<p style="text-align: center;"><b>Boileau</b> (50 seats, Level +2)</p>
<p><b>10:00–11:00</b></p> <p><b>Symposium 23</b>  <b>Skin cancer in the immunosuppressed patient</b>  <i>Chairs: Catherine Harwood, London, United Kingdom</i>  <i>Ulrike Leiter-Stöppke, Tuebingen, Germany</i></p> <p><b>10:00–10:12</b>  <b>Rare skin cancers in immunocompromised patients</b>  <i>Catherine Harwood, London, United Kingdom</i></p> <p><b>10:15–10:27</b>  <b>Prophylactic measures for skin tumours in OTR</b>  <i>Alexandra Geusau, Vienna, Austria</i></p> <p><b>10:30–10:42</b>  <b>Evaluation from targetable Immune Escape Mechanisms in chronic inflammatory skin diseases</b>  <i>Dagmar von Bubnoff, Bonn, Germany</i></p> <p><b>10:45–10:57</b>  <b>Systemic treatment with ICI in immunosuppressed patients</b>  <i>Ulrike Leiter-Stöppke, Tuebingen, Germany</i></p>	<p><b>10:00–10:50</b></p> <p><b>Free Communications 4</b>  <b>Non-melanoma skin cancer diagnosis and treatment II (lymphoma, merkel, sarcoma, etc.)</b>  <i>Chairs: Laurent Mortier, Lille, France</i>  <i>Chalid Assaf, Krefeld, Germany</i></p> <p><b>10:00–10:07</b>  <b>All-trans retinoic acid activity in Merkel cell carcinoma cells: implication of the retinoid pathway</b>  <i>Chiara Mazziotta, Ferrara, Italy</i></p> <p><b>10:10–10:17</b>  <b>Merkel cell carcinoma cells proliferation is inhibited by the DNA methyltransferases inhibitor guadecitabine via methylome modulation</b>  <i>John Charles Rotondo, Ferrara, Italy</i></p> <p><b>10:20–10:27</b>  <b>Whole transcriptome sequencing: Optimizing molecular classification and management of rare skin cancers.</b>  <i>Baptiste Louveau, Paris, France</i></p> <p><b>10:30–10:37</b>  <b>Skin adnexal carcinomas DNA genomic profiling uncovers oncogenic pathways and potential therapeutic targets.</b>  <i>Baptiste Louveau, Paris, France</i></p> <p><b>10:40–10:47</b>  <b>Integrated transcriptomics reveals cellular and molecular interactions in pruritic cutaneous T-cell lymphoma</b>  <i>Andrea Roggo, Zurich, Switzerland</i></p>

## Saturday, April 6<sup>th</sup>, 2024

Amphithéâtre Richelieu (1,000 seats, Floor +1)	Lulli (220 seats, Level -1)
11:20–11:30	
Poster & Oral Communication Awards	
11:30–12:00	
<b>Keynote Lecture 7</b> <i>Chair: John Haanen, Amsterdam, The Netherlands</i>  <b>Neoadjuvant treatment: current and future developments</b> <i>Sapna Patel, Houston, USA</i>	
12:00–12:30	
<b>Keynote Lecture 8</b> <i>Chair: Friedegund Meier, Dresden, Germany</i>  <b>How to treat melanoma brain metastasis</b> <i>Hussein Tawbi, Houston, United States</i>	
<b>12:30–12:45 Closing Ceremony</b>	

**Colbert**  
(100 seats, Level +2)


**Boileau**  
(50 seats, Level +2)



**SATELLITE  
SYMPOSIA  
AT A  
GLANCE**

<b>Amphithéâtre Richelieu</b> (1,000 seats, Floor +1)	<b>Lulli</b> (220 seats, Level -1)	<b>Colbert</b> (100 seats, Level +2)	<b>Boileau</b> (50 seats, Level +2)	<b>Thursday, April 4<sup>th</sup>, 2024</b>
<b>12:00–13:00</b> <b>Satellite Symposium 1</b> La Roche Posay				
<b>14:00–15:00</b> <b>Satellite Symposium 2</b> Bristol Myers Squibb				

<b>Amphithéâtre Richelieu</b> (1,000 seats, Floor +1)	<b>Lulli</b> (220 seats, Level -1)	<b>Colbert</b> (100 seats, Level +2)	<b>Boileau</b> (50 seats, Level +2)	<b>Friday, April 5<sup>th</sup>, 2024</b>
<b>12:00–13:00</b> <b>Satellite Symposium 3</b> MSD				
<b>14:00–15:00</b> <b>Satellite Symposium 4</b> Regeneron				
<b>15:00–16:00</b> <b>Satellite Symposium 5</b> Castle Biosciences		<b>15:00–15:30</b> <b>Satellite Symposium 6</b> Menarini Stemline		
		<b>15:30–16:00</b> <b>Satellite Symposium 7</b> Philogen		
	<b>16:30–17:30</b> <b>Satellite Symposium 8</b> Sun Pharma			



## SATELLITE SYMPOSIA PROGRAM

Thursday, April 4<sup>th</sup>, 2024

---



**Amphithéâtre Richelieu** 12:00–13:00

**SILVER SPONSOR** Satellite Symposium 1

**Skin care in oncology patients: ISKIMO expert consensus**

Chair: *Vincent Sibaud, Toulouse, France*

- 12:00–12:05 Introduction: What's known and what's new in cancer treatments and their skin side effects  
*Vincent Sibaud, Toulouse, France*
- 12:05–12:20 Dermocosmetics in patients with cancer: what are the expected benefits?  
*Dr. Delphine Kerob, Paris, France*
- 12:20–12:30 New recommendations for initiation and selection of skin care in all oncology patients: ISKIMO expert consensus  
*Florian Scotté, Paris, France*
- 12:35–12:45 Q&A – Panel discussion
- 



**Amphithéâtre Richelieu** 14:00–15:00

**GOLD SPONSOR** Satellite Symposium 2

**Challenging clinical questions: opinions, discussion, and audience questions**

Chair: *Olivier Michielin, Lausanne, Switzerland*

*Céleste Lebbé, Paris, France*

- 14:00–14:05 Welcome and Introductions  
*Olivier Michielin, Lausanne, Switzerland*
- 15:05–15:15 What is the optimal first-line treatment for a patient with metastatic melanoma?  
*Céleste Lebbé, Paris, France*
- 15:15–15:25 I have a patient with melanoma brain metastases, what is the preferred systemic therapy?  
*Olivier Michielin, Lausanne, Switzerland*
- 15:25–15:35 What options are available for a patient who has progressed on an anti-PD-1?  
*Céleste Lebbé, Paris, France*
- 15:35–15:45 How do I determine the risk–benefit of systemic therapy for a patient diagnosed with stage II melanoma?  
*Olivier Michielin, Lausanne, Switzerland*
- 15:45–15:55 Should I consider neoadjuvant therapy for my patient with macroscopic stage III melanoma?  
*Céleste Lebbé, Paris, France*
- 14:55–15:00 Summary and Close  
*Céleste Lebbé, Paris, France*
-

Friday, April 5<sup>th</sup>, 2024



Amphithéâtre Richelieu 12:00–13:00

**PLATINUM SPONSOR** Satellite Symposium 3

**Moving the needle forward: leading the way in treating skin cancers**

Chair: *Caroline Robert, Paris, France*

- 12:00–12:05 Welcome and opening remarks  
*Caroline Robert, Paris, France*
- 12:05–12:20 Navigating the early-stage melanoma setting:  
from neoadjuvant to adjuvant  
*Olivier Michielin, Geneva, Switzerland*
- 12:20–12:35 cSCC: where we are now and what's next?  
*Dirk Schadendorf, Essen, Germany*
- 12:35–12:55 Panel discussion and Q&A  
*Case-based*  
*All faculty*
- 12:55–13:00 Closing remarks  
*Caroline Robert, Paris, France*



Amphithéâtre Richelieu 14:00–15:00

**PLATINUM SPONSOR** Satellite Symposium 4

**Advancing perspectives for patients with non-melanoma skin cancer**

Chairs: *Paolo Bossi, Milan, Italy*  
*Ralf Gutzmer, Minden, Germany*  
*Céleste Lebbé, Paris, France*  
*Emily Ruiz, Boston, MA, USA*

- 14:00–14:02 Welcome and introductions  
*Céleste Lebbé, Paris, France*
- 14:02–14:14 Advancing perspectives on immunotherapy for patients with  
non-melanoma skin cancer  
*Céleste Lebbé, Paris, France*
- 14:14–14:26 Emerging treatment strategies in cutaneous squamous cell carcinoma  
*Emily Ruiz, Boston, MA, USA*
- 14:26–14:31 Panel discussion  
*All faculty*
- 14:31–14:43 Therapeutic challenges in advanced basal cell carcinoma  
*Ralf Gutzmer, Minden, Germany*
- 14:43–14:55 Clinical case discussions and future treatment perspectives  
*Paolo Bossi, Milan, Italy*
- 14:55–15:00 Panel discussion  
*All faculty*



**Amphithéâtre Richelieu** 15:00–16:00

**SILVER SPONSOR** Satellite Symposium 5

**Personalized risk assessment for skin cancer patients**

15:00–16:00 Personalized risk assessment for skin cancer patients  
*Moody Brent, Nashville, United States*



**Colbert** 15:00–15:30

**SILVER SPONSOR** Satellite Symposium 6

**BPDCN: why is a rare leukemia relevant in dermatology and dermatology-oncology**

Chair: *Ulrike Wehkamp, Hamburg, Germany*

15:00–15:15 Differential diagnosis of BPDCN: a dermatology-oncology perspective  
*Ulrike Wehkamp, Hamburg, Germany*

15:15–15:30 Importance and implications of early diagnosis of BPDCN  
*Krischan Braitsch, MD, Munich, Germany*



**Colbert** 15:30–16:00

**FURTHER SPONSOR** Satellite Symposium 7

**Intralesional treatments in skin cancers**

Chair: *Dario Neri, Zurich, Switzerland*

15:30–16:00 Intratumoral Therapies in Melanoma and other Skin Cancers  
*Thomas Eigentler, Berlin, Germany*

---



**Lulli** 16:30–17:30

**BRONZE SPONSOR** Satellite Symposium 8

**Optimal management of laBCC in 2024**  
**An open discussion on challenging situations in clinical practice**

Chair: *Nicole Basset-Seguín, Paris, France*

Discussants: *Paolo Bossi, Milan, Italy*  
*Carla Ferrándiz-Pulido, Barcelona, Spain*  
*Christoffer Gebhardt, Hamburg, Germany*

- 16:30–16:35 Introduction  
*Nicole Basset-Seguín*
- 16:35–16:45 To Treat or Not to Treat?  
*Nicole Basset-Seguín, All*
- 16:45–16:55 How to Manage CR?  
*Paolo Bossi,*  
*All*
- 16:55–17:05 What to do in case of PR?  
*Christoffer Gebhardt*  
*All*
- 17:05–17:15 How to Improve Tolerability?  
*Carla Ferrándiz-Pulido*  
*All*
- 17:15–17:25 When to Consider a Second-Line Therapy and Why?  
*All*
- 17:25–17:30 Conclusion  
*Nicole Basset-Seguín*
-





**SPONSORS  
AND  
EXHIBITORS**

# SPONSORS

## PLATINUM SPONSORS

---



**REGENERON**

## GOLD SPONSORS

---



## SILVER SPONSORS

---



## BRONZE SPONSORS

---

IMMUNOCORE





## SPONSORS AND EXHIBITORS

---




## CONGRESS APP SPONSOR

---

The EADO 2023 Congress App is kindly supported by  


## SPONSORED POSTER AWARDS

---

The research award is kindly supported by 


## SPONSORED POSTER EXHIBITION

---

The Poster Exhibition is kindly supported by  **NOVARTIS**

## WIFI SPONSOR

---

The EADO WIFI is kindly supported by . Free WIFI will be available within the congress area.  
The login details are as following: **Network: EADO2024 | Password: PARIS2024**

# Moving the needle forward: Leading the way in treating skin cancers

Palais des Congrès Versailles  
Amphithéâtre Richelieu  
Paris, France

**Friday, 05 April 2024**

12:00 - 13:00 (CET)

Scientific symposium sponsored by MSD

## Chair



**Caroline Robert**

Head of the Dermatology Unit  
Gustave Roussy  
Co-Director of the Melanoma  
Research Unit at INSERM 981  
Paris-Sud University  
Paris, France

## Faculty



**Olivier Michielin**

Professor of Medicine  
Université de Genève  
Chair of the Department of  
Oncology and the Precision  
Oncology Service  
Geneva University Hospital  
Geneva, Switzerland



**Dirk Schadendorf**

Director of the Department  
of Dermatology and the West  
German Cancer Center (WTZ)  
University Hospital Essen  
Essen, Germany

## Agenda

12:00 - 12:05

Welcome and opening remarks  
**Caroline Robert**

12:05 - 12:20

Navigating the early-stage melanoma  
setting: From neoadjuvant to adjuvant  
Q&A (5 minutes)  
**Olivier Michielin**

12:20 - 12:35

cSCC: Where we are now and what's next?  
Q&A (5 minutes)  
**Dirk Schadendorf**

12:35 - 12:55

Panel discussion and Q&A (case-based)  
**Caroline Robert, Olivier Michielin,  
Dirk Schadendorf**

12:55 - 13:00

Closing remarks  
**Caroline Robert**

20th EADO Congress 2024 Industry  
Satellite Symposium

# New Perspectives on Perioperative Treatment for Non-melanoma Skin Cancer

Friday, 05 April 2024 | 14:00-15:00 CEST | PARIS, FRANCE PALAIS DES CONGRÈS VERSAILLES



**Prof. Céleste Lebbé,  
Symposium Chair**  
Paris Nord University and  
Saint Louis Hospital  
Paris, France



**Dr. Emily Ruiz**  
Harvard Medical School and  
Dana-Farber Brigham  
Cancer Center  
Boston, MA, USA



**Prof. Ralf Gutzmer**  
Johannes Wesling Medical  
Center, Ruhr University  
Bochum Campus  
Minden, Germany



**Prof. Paolo Bossi**  
Humanitas University and  
Humanitas Cancer Center  
Milan, Italy

## PROGRAMME

**Welcome and Introductions**

Prof. Céleste Lebbé

**Advancing Perspectives on Immunotherapy for Patients with  
Non-melanoma Skin Cancer**

Prof. Céleste Lebbé

**Emerging Treatment Strategies in Cutaneous Squamous Cell Carcinoma**

Dr. Emily Ruiz

**Therapeutic Challenges in Advanced Basal Cell Carcinoma**

Prof. Ralf Gutzmer


**Clinical Case Discussions and Future Treatment Perspectives**

Prof. Paolo Bossi

**Panel Discussion**

All Faculty

# Challenging Clinical Questions in Melanoma: Expert Perspectives on Management Options



Thursday, 4 April 2024 | 14:00 – 15:00 CEST

Room 1, Amphithéâtre Richelieu | Versailles Palais des Congrès, Paris, France

Available On Demand Until Sunday, 20 October 2024



Faculty

**Céleste Lebbé, MD, PhD**

AP-HP Hôpital Saint-Louis  
Paris, France



Faculty

**Olivier Michielin, MD, PhD**

Hôpitaux Universitaires de Genève  
Swiss Cancer Center Léman (SCCL)  
Lausanne, Switzerland

14:00–14:05  
(5 minutes)

## Welcome and Introduction

Olivier Michielin

14:05–14:55  
(50 minutes)

## Challenging Clinical Questions: Opinions, Discussion, and Audience Questions

What is the optimal first-line treatment for a patient with metastatic melanoma?

Céleste Lebbé

I have a patient with melanoma brain metastases, what is the preferred systemic therapy?

Olivier Michielin

What options should I consider for a patient who has progressed on prior anti-PD-1-based therapy?

Céleste Lebbé

How do I determine the risk–benefit of systemic therapy for a patient diagnosed with early stage (IIB/C) melanoma?

Olivier Michielin

Should I consider neoadjuvant therapy for my patient with macroscopic stage III melanoma?

Céleste Lebbé

14:55–15:00  
(5 minutes)

## Summary and Close

Céleste Lebbé

This Industry-Sponsored Symposium Is a Medical Education Activity That Is Organized and Funded by the Medical Department of Bristol Myers Squibb.



# RELATIVITY-127

## A Clinical Study for Patients with Advanced or Unresectable Melanoma



The **RELATIVITY-127** clinical study is testing the non-inferiority of subcutaneous nivolumab + relatlimab fixed dose combination versus intravenous nivolumab + relatlimab fixed dose combination, which presents the possibility of drastically reducing dosing times from the 30–60 minutes expected for IV, down to 3–5 minutes for SC.

Read the full study eligibility guidelines and refer your advanced stage melanoma patient into the study.

VISIT STUDY >



### Is your patient eligible?

#### To be eligible, your patient must:

- Be 12 years of age or older. Participants who are 12 to 17 years of age (adolescents) must weigh 40 kg or more at the time of signing the informed consent (assent)  
*Exception: Local regulations and/or institutional policies may not allow for participants 12 to 17 years of age (adolescent population) to participate. In those cases, the eligible participant population is 18 years of age and older.*
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of  $\leq 1$  (for adults  $\geq 18$  years of age)/ Lansky Performance Score  $\geq 80\%$  for adolescents ( $\geq 12$  to  $< 18$  years of age)
- Have histologically confirmed Stage III (unresectable) or Stage IV (metastatic) melanoma, per the American Joint Committee on Cancer (AJCC) staging system; (8th edition)
- Be treatment naïve (i.e., no prior systemic anticancer therapy for unresectable or metastatic melanoma)

#### Your patient must not:

- Have active brain metastases or leptomeningeal metastases  
*Note: Some exceptions are admissible.*
- Have ocular melanoma
- Have an active, known, or suspected autoimmune disease  
*Note: Some conditions are admissible.*

### Study design

**Screening** period includes signing of applicable Informed Consent forms, eligibility assessment, tumour sample collection, imaging and various assessments. Randomisation is 1:1 to either nivolumab + relatlimab FDC administered intravenously or nivolumab + relatlimab FDC administered subcutaneously.

**Treatment** cycles take place once every four weeks and continue until unacceptable toxicity, withdrawal of consent, lost to follow-up, disease progression, death or termination of the study by the sponsor.

Thank you for considering referring your advanced stage melanoma patients into the clinical study.

### Additional criteria apply

Visit our study website at:

[bmsstudyconnect.com/melanoma](https://bmsstudyconnect.com/melanoma)

to get more eligibility information

For resectable Stage III and unresectable or metastatic Stage IV BRAF V600 positive melanoma

## TAFINLAR + MEKINIST— Expanding life's possibilities for the journey ahead

With more than 200,000 patients treated worldwide, TAFINLAR + MEKINIST is **the first and only oral targeted therapy** with both 5-year OS data in the metastatic setting and 5-year RFS data in the adjuvant setting.<sup>1-5</sup>

**Choose TAFINLAR + MEKINIST  
for rapid efficacy that lasts.**<sup>4-6</sup>



OS, overall survival; RFS, relapse-free survival.

**References:** **1.** Data on file. BRAF Inhibitors Worldwide Numbers. Novartis Pharmaceuticals Corp; December 2021. **2.** TAFINLAR Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2021. **3.** MEKINIST Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2021. **4.** Supplement to: Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. *N Engl J Med.* 2019;381(7):626-636. **5.** Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. *N Engl J Med.* 2020;383(12):1139-1148. **6.** Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. *N Engl J Med.* 2017;377(19):1813-1823.

Please see Summary of Product Characteristics for TAFINLAR and Summary of Product Characteristics for MEKINIST in booth.



# Pierre Fabre Laboratories



## New ways to care

At Pierre Fabre Laboratories, we have a passion for addressing clinical challenges through innovative solutions, **keeping patients at the core of our efforts**. The fight against cancer is our main priority in medical care. We take a holistic approach to cancer care focusing not only on **TREATMENT**, but also **PREVENTION** and **SUPPORT**.



LABORATOIRES

Pierre Fabre

*Every time we care for a single person, we make the whole world better*

HQ--02-24-2400019

**CASTLE**  
BIOSCIENCES

## Changing the way patients are diagnosed and managed

Driven by a shared purpose, we are transforming the diagnosis and treatment of dermatological cancers, enabling more precise testing for better informed decisions for cutaneous melanoma and squamous cell carcinoma.



LEARN MORE

**Decision Dx**  
► Melanoma

Provides comprehensive, personalized, genomic tumor information to guide management for patients with cutaneous melanoma

**Decision Dx**  
► SCC

Identifies the biological risk of metastasis and informs treatment and management decisions for patients with squamous cell carcinoma

**MyPath**  
► Melanoma

Aids in the diagnosis and management for patients with ambiguous melanocytic lesions





# DO YOU SEE IT? LOOK AGAIN

## **Blastic Plasmacytoid Dendritic Cell Neoplasm.**

A very rare, clinically aggressive hematologic malignancy which often goes misdiagnosed.<sup>1</sup>

If something doesn't feel right, speak with your clinical team.



**Raise your  
BPDCN  
awareness**



**Stemline**  
A Menarini Group Company

1. Sullivan JM and Rizzieri DA. *Hematology Am Soc Hematol Educ Prog* 2016; 2016(1):16–23.

# IMMUNOCORE

Pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients.

**Science to transform lives.**




immunocore.com

We are actively recruiting patients with advanced cutaneous melanoma.

**Visit [clinicaltrials.gov](https://clinicaltrials.gov) to learn more.**



CM-EU-2400002  
Prepared on 06/02/2024



Finally, a 5-day treatment that gets rid of my lesions without interfering in my daily life.

**KLISYRI®** matches both patient and derms needs, as demonstrated in PROAK Study <sup>1,2</sup>



Overall, it provides a satisfactory experience and really works for my patients, so I feel confident to use it again.



## EFFICACY<sup>1,2</sup>

Provides and maintains over **70%** complete/partial clearance at 24 weeks<sup>1,2</sup>

## SATISFACTION<sup>1,2</sup>

**76.6%** of patients stated that LSRs were less severe vs previous topicals and considered it **more convenient**<sup>11</sup>

## WILLINGNESS TO RETREAT<sup>\*\*1,2</sup>

More than **80%** of patients and dermatologists are willing for retreatment<sup>4</sup>

For more information about this medicinal product, please refer to the local Summary of Product Characteristics (SmPC). This medicinal product may not be marketed in all countries (for more information see <https://www.ema.europa.eu/en/medicines/human/EPAR/klisyri>)

Klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis of the face or scalp in adults, as indicated in the SmPC.

<sup>1</sup>PROAK study: Observational, phase IV study conducted in 290 patients who had initiated treatment with KLISYRI® that evaluated PROs and ClinROs among adult patients with AKs on face or scalp in real-world clinical practice in the U.S. Outcomes assessments were made at 8 and 24 weeks. <sup>2</sup>KLISYRI®, in the observational study PROAK, has demonstrated effectiveness in AK management, improved QoL as early as week 8, and shown high levels of treatment satisfaction, compared to patient's previous treatments. <sup>3</sup>EPQ questionnaire: Overall satisfaction: Compared to your previous experience with topical treatment X for AK, how would you rate your overall satisfaction (considering factors such as convenience/ ease of use, duration and severity of skin reactions, impact on patient's daily life, etc.) with tirbanibulin treatment? <sup>4</sup>71.2% of patients considered KLISYRI® more convenient, according to EPQ questionnaire in the PROAK study. <sup>5</sup>EPQ questionnaire: In case you need to be re-treated for AK, how likely are you to consider treatment Y again? <sup>6</sup>11

LSRs: local skin reactions; PROAK: Patient Reported Outcomes in Actinic Keratosis.

References: 1. Schlesinger T, et al. Safety and Tolerability of Tirbanibulin 1% Treatment of Actinic Keratosis on Face and Scalp in Routine Clinical Practice Across the U.S. (PROAK Study) *Skin*.2023;7(3):771-787. 2. Schlesinger T, et al. Patient- and Clinician-Reported Outcomes of Tirbanibulin 1% in the Treatment of Actinic Keratosis on the Face and Scalp (PROAK Study). *SKIN The Journal of Cutaneous Medicine* 2023;7(6), s262. 3. Berman B, et al. Developing a Questionnaire for Assessing Clinician and Patient-Reported Outcomes in Actinic Keratosis: Results From an Expert Panel. *JAAD International* 2023; <https://doi.org/10.1016/j.jdin.2023.09.006>.




**METASTATIC  
MERKEL CELL  
CARCINOMA**

**BAVENCIO**<sup>®</sup>  
avelumab 20 mg/mL  
Concentrate for solution for infusion

JAVELIN MERKEL 200 TRIAL

**DURABLE  
RESPONSE  
IN MERKEL CELL  
CARCINOMA**<sup>1-3</sup>  
AND  
**EXTENDED OS  
AFTER >4 YEARS  
OF FOLLOW-UP**<sup>2,3,\*</sup>



**REAL-WORLD DATA** AVAILABLE IN **OVER 600 PATIENTS** SUPPORT AND SUPPLEMENT THE DURABLE RESPONSES AND PROLONGED SURVIVAL SEEN IN CLINICAL TRIAL DATA.<sup>4-12</sup>

REAL-WORLD  
EVIDENCE

1L

2L+

RW ORRs  
up to:<sup>4-8,†</sup>

~68%

RW  
median OS  
up to:<sup>6,7,11,12,‡</sup>

52.0  
MONTHS

\*>4 years in 1L and >5 years in 2L+.

<sup>†</sup>ORRs reported across RW studies in ~450 patients.<sup>4-8</sup> <sup>‡</sup>OS rates reported across RW studies in ~200 patients.<sup>6,7,11,12</sup>

**BAVENCIO**<sup>®</sup> is indicated as monotherapy for the treatment of adult patients with mMCC.<sup>1</sup>

Please [click here](#) for the Summary of Product Characteristics.

1L=first-line; 2L+=second-line or later; mMCC=metastatic Merkel cell carcinoma; ORR=objective response rate; OS=overall survival; RW=real-world.

**References:** 1. BAVENCIO<sup>®</sup> EU SmPC, January 2024. 2. D'Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. *ESMO Open*. 2021;6(6):100290. 3. D'Angelo SP, Lebbé C, Mortier L, et al. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 trial. *SITC 2022*. Abstract N. 604. 4. Walker JW, Lebbé C, Grignani G, et al. Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. *J Immunother Cancer*. 2020;8(1):e000313. 5. Levy S, Aarts MJB, Eskens FALM, et al. Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort. *J Immunother Cancer*. 2020;8(2):e001076. 6. Bhatia S, Nghiem P, Veeranki SP, et al. Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study. *J Immunother Cancer*. 2022;10(8):e004904. 7. Cowey CL, Liu FX, Kim R, et al. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel. *Future Oncol*. 2021;17(18):2339-2350. 8. Yamazaki N, Kiyohara Y, Sato M, et al. A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan. *Ann Oncol*. 2022; abstract N. 407P. 9. Bhanegaonkar A, Liu FX, Boyd M, et al. Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel. *Oncologist*. 2021;26(9):e1633-e1643. 10. Averbuch I, Stoff R, Miodovnik M, et al. Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma-A multicenter real-world experience in Israel. *Cancer Med*. 2023;12(11):12065-12070. 11. Knott C, Mahmoudpour SH, Kearney M, et al. First-line Treatment (Tx) Patterns and Overall Survival (OS) of Patients (Pts) With Advanced Merkel Cell Carcinoma (aMCC) in England From 2013-2022: Results of a Nationwide Observational Cohort Study. ESMO congress 20-24 October 2023, Madrid, Spain, abstract N. 1147P. 12. Becker JC, Mahmoudpour SH, Schadendorf D, et al. Clinical characteristics and survival of patients with advanced Merkel cell carcinoma (MCC) treated with avelumab: analysis of a prospective German MCC registry (MCC TRIM). ESMO congress 20-24 October 2023, Madrid, Spain, abstract N. 1145P.

This material is intended for healthcare professionals only. It is not aimed at French healthcare professionals.

©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. BAVENCIO is a registered trademark of Merck KGaA, Darmstadt, Germany or its affiliates. FR-AVE-00101 01/24

**MERCK**

Sun Pharma Symposium  
**Save the Date**

Friday 5 April 2024, 16:30 – 17:30

Room 2

## Optimal Management of laBCC in 2024

An Open Discussion on Challenging Situations in Clinical Practice

### Speakers



Nicole Basset-Seguin  
(chair)  
Saint Louis Hospital,  
Paris, France



Carla Ferrándiz-Pulido  
Vall d'Hebron University  
Hospital, Barcelona,  
Spain



Paolo Bossi  
Humanitas University  
Hospital, Milan,  
Italy



Christoffer Gebhardt  
University Hospital,  
Hamburg-Eppendorf,  
Germany

### Discussion Topics:

- To treat or not to Treat?
- How to Manage complete response?
- What to do in case of partial response?
- How to improve tolerability?
- When to Consider a Second-Line Therapy?



FEB 24 - SUN/ELJ/CORP/1223/028A



# Pioneering the Science of Time

Every day, we seek to transform science into more time for life. Time to be with families, time to be productive community members, time to feel the small moments of joy that shape our lives.

